Compare Inovio Pharmaceuticals Inc (INO) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Riot Platforms Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Riot Platforms Inc trades at $16.89 (market cap $6.32B). The key difference: Riot Platforms Inc is far larger — about 56.3× Inovio Pharmaceuticals Inc's market cap, and Riot Platforms Inc is more actively traded (30,571,756 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Riot Platforms Inc for 16 Days on average.
| INO | RIOT | |
|---|---|---|
Market Cap | $112.19M | $6.32B |
Volume | 3,201,278 | 30,571,756 |
Sector | Health | Financials |
52-Week High | $2.65 | $28.67 |
52-Week Low | $0.66 | $11.83 |
Typical Hold Time | 43 Days | 16 Days |
Enterprise Value | $83.51M | $6.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
RIOT Platforms trades at $16.885, down 8.93% on the day, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported significant losses with a net income margin of -196.28% in 2026, though revenue grew to $675 million. Recent strategic shifts toward AI data center leasing, including a $9.1 billion contract, highlight transformation efforts amid challenging profitability.
While analyst consensus remains strongly bullish with a $31.64 price target, substantial execution risks and persistent negative earnings pose challenges. The stock's outlook hinges on successful monetization of AI infrastructure contracts and improved operational efficiency to stem cash flow deficits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
